Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | GALR2 | O43603 | 1/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431617 | 1.00 | KMT2A (0.48) | KMT2ALTA4HCHRM4KAT2BGALR2 | |
| SCHEMBL8123690 | 0.90 | LTA4H (0.52) | KMT2ALTA4HCHRM4HTTBCHE | |
| SCHEMBL4048096 | 0.85 | LTA4H (0.53) | LTA4HDRD4BCHE | |
| SCHEMBL4290142 | 0.85 | LTA4H (0.46) | KMT2ALTA4HCHRM4DRD4BCHE | |
| SCHEMBL4287262 | 0.83 | LTA4H (0.47) | KMT2ALTA4HDRD4BCHE | |
| SCHEMBL4289743 | 0.81 | LTA4H (0.49) | LTA4HDRD4BCHE | |
| SCHEMBL4289616 | 0.80 | LTA4H (0.48) | KMT2ALTA4HDRD4BCHE | |
| SCHEMBL4290899 | 0.78 | LTA4H (0.48) | LTA4HHTTBCHE | |
| SCHEMBL4293738 | 0.77 | HDAC6 (0.41) | KMT2ALTA4HCHRM4 | |
| SCHEMBL4284730 | 0.76 | ACHE (0.46) | KMT2ALTA4HCHRM4DRD4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885LTA4H 1197/4885CHRM4 3875/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885LTA4H 1197/4885CHRM4 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.